Research progress in herpes zoster vaccine based on glycoprotein E

VernacularTitle:基于糖蛋白E的带状疱疹疫苗研究进展
Author: Mengyao YANG ¹ ; Yinhui PEI ; Zhaojun DUAN
Author Information

1. 华北理工大学基础医学院　河北省慢性疾病基础医学重点实验室，唐山　063000
Keywords: Varicella-zoster virus; Herpes zoster vaccine; Glycoprotein E
From: Chinese Journal of Experimental and Clinical Virology 2024;38(5):578-585
CountryChina
Language:Chinese
Abstract: After the first infection with varicella-zoster virus causes chickenpox and recovers, it will lurk in the spinal ganglia and other parts of the body. As people age and immunity declines, the virus reactivates and causes neurotropic bands of blisters that mainly affect the skin of the waist and chest, known as herpes zoster. At present, there is no specific drug that can prevent and control the infection and recurrence of varicella-zoster virus infection. In view of the unique immunogenic advantages of varicella-zoster virus glycoprotein E (gE), it has become an important target antigen for the development of herpes zoster vaccine at home and abroad. This article reviews the current research progress of new gE-based herpes zoster vaccine in the world, hoping to provide reference for the research and development of a new generation of herpes zoster vaccine in China.